Sorafenib
Tumour Vessel Targeting Agents – Tyrosine Kinase Inhibitor of BRAF, CRAF, KIT, Flt-3, RET, VEGFR, and PDGFR-β
Description of the anti-cancer agent sorafenib; a tyrosine kinase inhibitor of BRAF, CRAF, KIT, Klt-3, RET, VEGFR, and PDGFR-β.
ESMO members: your membership includes full access to ESMO's Anti-Cancer Agents Factsheets. Sign in now to gain access to this page.
Not yet an ESMO member? Find out more about the benefits of becoming an ESMO member.